1089147-17-0

Basic information

• Product Name: (2R,3R)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3-(prop-2-ynyloxy)chroman
• Synonyms: (2R,3R)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3-(prop-2-ynyloxy)chroman
• CAS NO: 1089147-17-0
• Molecular Weight: 688.82
• Mol File: 1089147-17-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2R,3R)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3-(prop-2-ynyloxy)chroman(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3R)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3-(prop-2-ynyloxy)chroman(1089147-17-0)
• EPA Substance Registry System: (2R,3R)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3-(prop-2-ynyloxy)chroman(1089147-17-0)

Safety Data

• Hazardous Substances Data: 1089147-17-0(Hazardous Substances Data)

Upstream product

• 480-18-2 (-)-epitaxifolin 
• 100-39-0 benzyl bromide 
• 106-96-7 propargyl bromide 
• 87292-49-7 5,7,3',4'-tetra-O-benzylepicatechin 

Downstream Products

• 1089147-06-7 C₅₇H₅₅N₅O₁₀ 
• 1089147-09-0 C₅₃H₄₈N₈O₆ 
• 1204484-93-4 C₆₄H₅₈N₄O₈ 
• 1204484-89-8 C₆₃H₅₆N₄O₇ 

Relevant articles and documents

Design, synthesis and characterization of novel inhibitors against mycobacterial β-ketoacyl CoA reductase FabG4

We report the design and synthesis of triazole-polyphenol hybrid compounds 1 and 2 as inhibitors of the FabG4 (Rv0242c) enzyme of Mycobacterium tuberculosis for the first time. A major advance in this field occurred only a couple of years ago with the X-ray crystal structure of FabG4, which has helped us to design these inhibitors by the computational fragment-based drug design (FBDD) approach. Compound 1 has shown competitive inhibition with an inhibition constant (Ki) value of 3.97 ± 0.02 μM. On the other hand, compound 2 has been found to be a mixed type inhibitor with a Ki value of 0.88 ± 0.01 μM. Thermodynamic analysis using isothermal titration calorimetry (ITC) reveals that both inhibitors bind at the NADH co-factor binding domain. Their MIC values, as determined by resazurin assay against M. smegmatis, indicated their good anti-mycobacterial properties. A preliminary structure-activity relationship (SAR) study supports the design of these inhibitors. These compounds may be possible candidates as lead compounds for alternate anti-tubercular drugs. All of the reductase enzymes of the Mycobacterium family have a similar ketoacyl reductase (KAR) domain. Hence, this work may be extrapolated to find structure-based inhibitors of other reductase enzymes. The Royal Society of Chemistry.

Design, synthesis and RNase A inhibition activity of catechin and epicatechin and nucleobase chimeric molecules

Several novel catechin/epicatechin and nucleobase chimeric molecules 1-6 have been synthesized via azide-alkyne click chemistry. The structures of these hybrids have been confirmed by NMR and mass spectroscopic data. The synthesized molecules were tested